Macomber Lori 4

What Happened Lori Macomber, EVP, Chief Financial Officer & Treasurer of Karyopharm Therapeutics (KPTI), sold 1,626 shares in an open-market, broker-assisted transaction on February 3, 2026 at $6.30 per share, grossing $10,244. This was a sale (routine disposition) rather than a purchase.

Key Details

• Transaction date and price: 2026-02-03, 1,626 shares at $6.30 per share (total $10,244).
• Transaction code: S (Sale).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: The sale was effected under a durable automatic sale instruction plan adopted by the reporting person on December 19, 2024; it was a broker-assisted sale to satisfy withholding tax liability on vested restricted stock units and was not a discretionary trade by the reporting person (Footnote F1).
• Filing timing: Reported on February 4, 2026 for a February 3, 2026 transaction — appears filed promptly.

Context This sale was executed specifically to cover tax withholding on vested restricted stock units and was governed by an automatic, non-discretionary plan. Such sales to satisfy tax obligations are common and do not necessarily indicate the insider’s view on the company's prospects.